Biomarin Pharmaceutical Stock Investor Sentiment

BMRN Stock  USD 87.34  1.27  1.43%   
About 56% of Biomarin Pharmaceutical's investor base is looking to short. The analysis of the overall investor sentiment regarding Biomarin Pharmaceutical suggests that many traders are alarmed. Biomarin Pharmaceutical's investor sentiment overview provides quick insight into current market opportunities from investing in Biomarin Pharmaceutical. The current market sentiment, together with Biomarin Pharmaceutical's historical and current headlines, can help investors time the market. In addition, many technical investors use Biomarin Pharmaceutical stock news signals to limit their universe of possible portfolio assets and to time the market correctly.

Panic Vs Confidence

44

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Biomarin Pharmaceutical's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Biomarin Pharmaceutical.
Biomarin Pharmaceutical stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Biomarin daily returns and investor perception about the current price of Biomarin Pharmaceutical as well as its diversification or hedging effects on your existing portfolios.

Biomarin Historical Sentiment

Although Biomarin Pharmaceutical's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Biomarin, such as negative comments on social media and news outlets, may cause fear in the market and push Biomarin Pharmaceutical's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Biomarin.
  

Biomarin Pharmaceutical Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Biomarin Pharmaceutical can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Biomarin Pharmaceutical Historical Investor Sentiment

Investor biases related to Biomarin Pharmaceutical's public news can be used to forecast risks associated with an investment in Biomarin. The trend in average sentiment can be used to explain how an investor holding Biomarin can time the market purely based on public headlines and social activities around Biomarin Pharmaceutical. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Biomarin Pharmaceutical's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Biomarin Pharmaceutical and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Biomarin Pharmaceutical news discussions. The higher the estimate score, the more favorable the investor's outlook on Biomarin Pharmaceutical.

Biomarin Pharmaceutical Maximum Pain Price across 2024-04-19 Option Contracts

Biomarin Pharmaceutical's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Biomarin Pharmaceutical close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Biomarin Pharmaceutical's options.
a day ago at zacks.com         
Why Is Beam Therapeutics Down 22.1 percent Since Last Earnings Report?
zacks News
2 days ago at finance.yahoo.com         
Global Skeletal Dysplasia Market Projected to Reach USD 3.92 Billion by 2028, Growing at a CAGR of 7...
Yahoo News
few days ago at businesswire.com         
CORRECTING and REPLACING Jean-Jacques Bienaim Appointed Chairman of the Board at Owkin
businesswire News
few days ago at businesswire.com         
Acquisition by George Davis of 20840 shares of Biomarin Pharmaceutical subject to Rule 16b-3
businesswire News
few days ago at news.google.com         
Gulf International Bank UK Ltd Trims Stock Position in BioMarin Pharmaceutical Inc. - Defense World
Google News at Macroaxis
six days ago at news.google.com         
BioMarin Pharmaceutical Inc. Stock Position Cut by Baker Tilly Wealth Management LLC - Defense World
Google News at Macroaxis
over a week ago at benzinga.com         
Major Decision Dennis Slamon Exercises Options, Realizing 50K At Biomarin Pharmaceutical
benzinga news
over a week ago at finance.yahoo.com         
Orchard sets out to sell worlds priciest gene therapy
Yahoo News
over a week ago at news.google.com         
Vanguard Group Inc. Decreases Stake in BioMarin Pharmaceutical Inc. - MarketBeat
Google News at Macroaxis
over a week ago at www.macroaxis.com         
Disposition of 372 shares by Erin Burkhart of Biomarin Pharmaceutical at 83.87 subject to Rule 16b-3
Macroaxis News
over a week ago at finance.yahoo.com         
4 Extraordinary Growth Stocks Youll Regret Not Buying in the New Nasdaq Bull Market
Yahoo News
over a week ago at finbold.com         
Disposition of 22580 shares by Jeff Ajer of Biomarin Pharmaceutical at 83.87 subject to Rule 16b-3
news
over a week ago at finbold.com         
Miracle growth Discover the biotech stock behind decades of jaw-dropping returns
news
over two weeks ago at statnews.com         
Gerons resurgence might have been short-lived
news
over two weeks ago at finance.yahoo.com         
New Data to be Presented for BioMarins VOXZOGO in Children with Hypochondroplasia and Achondroplasia...
Yahoo News
Far too much social signal, news, headlines, and media speculation about Biomarin Pharmaceutical that are available to investors today. That information is available publicly through Biomarin media outlets and privately through word of mouth or via Biomarin internal channels. However, regardless of the origin, that massive amount of Biomarin data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Biomarin Pharmaceutical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Biomarin Pharmaceutical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Biomarin Pharmaceutical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Biomarin Pharmaceutical alpha.

Biomarin Pharmaceutical Performance against NYSE Composite

 Price Growth (%)  
       Timeline  
1
BioMarin Pharmaceutical Inc. Shares Sold by Virtus ETF Advisers LLC
02/02/2024
2
BioMarin Pharmaceutical Beats Q4 Earnings and Revenue Estimates
02/22/2024
3
Royal Bank of Canada Reaffirms Sector Perform Rating for BioMarin Pharmaceutical
02/26/2024
4
Acquisition by George Davis of 20840 shares of Biomarin Pharmaceutical subject to Rule 16b-3
02/29/2024
5
Caisse DE Depot ET Placement DU Quebec Has 3.96 Million Stock Holdings in BioMarin Pharmaceutical Inc.
03/04/2024
6
BioMarin Pharmaceutical Inc. Shares Sold by Qube Research Technologies Ltd
03/05/2024
7
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
03/07/2024
8
Insider Sell President, Worldwide RD Henry Fuchs Sells 35,341 Shares of Biomarin ...
03/08/2024
9
Braun Stacey Associates Inc. Sells 177,727 Shares of BioMarin Pharmaceutical Inc.
03/12/2024
10
Disposition of 22580 shares by Jeff Ajer of Biomarin Pharmaceutical at 83.87 subject to Rule 16b-3
03/15/2024
11
Disposition of 372 shares by Erin Burkhart of Biomarin Pharmaceutical at 83.87 subject to Rule 16b-3
03/18/2024
12
Major Decision Dennis Slamon Exercises Options, Realizing 50K At Biomarin Pharmaceutical
03/21/2024
13
Why Is Beam Therapeutics Down 22.1 percent Since Last Earnings Report
03/28/2024
When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:

Complementary Tools for Biomarin Stock analysis

When running Biomarin Pharmaceutical's price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Money Managers
Screen money managers from public funds and ETFs managed around the world
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Valuation
Check real value of public entities based on technical and fundamental data
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.98
Earnings Share
0.87
Revenue Per Share
12.88
Quarterly Revenue Growth
0.202
Return On Assets
0.0163
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.